Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads

Executive Summary

FDA's early intervention regarding misleading advertisements for King's morphine product Embeda gave the company a head start on reviewing its promotional pieces, but it did not mean the company could escape from the official warning letter

You may also be interested in...

When Is An Abuse-Deterrent Claim FDA Approved?

Agency says it is seeing confusion in the marketplace when it comes to distinguishing between agency-approved labeling claims and advertising about products that are intended to be abuse deterrent.

FDA Phone Call Preceded Untitled Letter To Lilly Over Amyvid

Lilly promised to remove offending images from promotional materials for its imaging product, but the agency followed up with a “notice of violation” letter two months later anyway.

Tamper-Resistance Could Allow New Opioid Formulations To Differentiate Themselves

A claim for tamper-resistance rather than broad abuse-deterrence appears to be the immediate path forward for companies seeking to differentiate a new opioid product by its ability to impede recreational use.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts